Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the oral contribution of the Parliamentary Under Secretary of State for Mental Health and Inequalities on 22 March, Col 488, what recent discussions he has had with BioMarin, the manufacturer of Kuvan, on the pricing of that drug.

NHS England has advised that they have, over the last three years, received fewer than 10 Individual Funding Requests applications and therefore there have been fewer than 10 approvals relating to the use of Kuvan.

The Secretary of State for Health and Social Care has not had further recent discussions with the manufacturer (BioMarin) since the oral contribution of my Rt. hon. Friend the Parliamentary Under Secretary of State for Mental Health and Inequalities (Jackie Doyle-Price).